Friday, 19 Jul 2019

You are here

RheumNow Week in Review – 15 July 2016

Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.

  1. FDA Approves Xiidra (Lifitegrast), an LFA-1 agonits for Dry Eyes. 
  2. FDA Arthritis Advisory Committee Votes 26-0 to Recommend Approval of Adalimumab Biosimilar (Amgens ABP-501).  
  3. Sandoz Etanercept Biosimilar (GP-2015) Unanimously (20-0) Voted for Approval by FDA Arthritis Advisory Committee.  
  4.  FDA Says Cryotherapy, not approved, lacks evidence and poses risks.  http://rheumnow.com/content/fda-says-cryotherapy-lacks-evidence-poses-risks
  5. Vagal Stimulation Decreases Proinflammatory Cytokine Production and Rheumatoid Disease Activity.  
  6. Lupus panniculitis appears as indurated nodules/plaques with lipoatrophy, usually over the proximal extremities & trunk. Important to get a deep Biopsy.  Usual treatments include hydroxychloroquine, steroid, dapsone, others reviewed. https://t.co/CJ5uJHxtcF
  7. In 428 SpA pts, BMI (obesity) had no effect on ASDAS. BMI weakly correlates with CRP, other PRO's. https://t.co/FcTfEicYpN
  8. Small study of Bactrim in GPA (Wegeners) shows 25% relapse w/ continued Rx vs 45% relapse with Bactrim withdrawal. https://t.co/IQksnzI5mk
  9. German RABBIT registry study >13K pts shows an increased risk of lower GI perforations with Actemra (2.7/1000PY), with a four fold higher risk than other therapys.  Nearly 25% of such patients died. https://t.co/u9A4TRFMso
  10. Prevalence of gout increasing in EU from 1.7% to 2.5%; in the US to 4%. Gout is becoming epidemic. https://t.co/zSSRbTId73
  11. 100k German RA compared to 500k controls: RA patients were vaccinated more; but more pneumonia hospitalizations were seen in regions with low or no vaccination https://t.co/HxOIIOf0rP
  12. 234 RA patients treated with Rituxan for a mean of 28 mos. Showed a retention rate of 57%. Discontinuatoins were associated with higher age, greater swollen joint counts, lack of concomitant MTX use.  https://t.co/QRLR9mgP84

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – Don’t Take My Advice (7.19.19)

Dr. Jack Cush reports the news and new journal articles from the past week on RheumNow.com.

RheumNow Podcast – Boiling Hot MAS (7.12.19)

Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com. PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

EULAR 2019 – Day 3 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.